Alzheimer’s disease is one of the most challenging brain disorders of our time. It slowly destroys memory, thinking, and independence, and it affects millions of people around the world.
There is still no cure, and most treatments only help with symptoms instead of stopping the disease itself. But a team of scientists at the Federal University of ABC (UFABC) in Brazil may have found a promising new approach.
They have created a simple chemical compound that could help reduce one of the main drivers of Alzheimer’s: the buildup of beta‑amyloid plaques in the brain.
These plaques form when sticky fragments of a protein called amyloid gather between nerve cells. Over time, they trigger inflammation, damage neurons, and interfere with how brain cells communicate. Because this buildup begins many years before symptoms appear, finding a way to reduce or prevent it is one of the biggest goals in Alzheimer’s research.
The Brazilian team tested their new compound in several stages—computer simulations, lab-grown cells, and live animals. The results were very encouraging. The compound seems to work by acting as a copper chelator. This means it binds to excess copper found inside beta‑amyloid plaques.
Scientists have known for about ten years that copper ions can help the plaques form and grow. People with certain genetic mutations or problems with copper‑transporting enzymes may accumulate more copper in the brain, increasing plaque formation. By removing that copper, the new compound appears to weaken or break apart the plaques.
The researchers designed molecules capable of crossing the blood–brain barrier, which is one of the biggest challenges in drug development.
This barrier protects the brain from harmful substances, but it also keeps out many medicines. Of the ten new molecules created in the study, three were tested in rats with induced Alzheimer’s disease. One stood out because it was both effective and safe.
In these animal tests, the compound produced strong benefits. Rats treated with the molecule showed less memory loss and fewer problems with learning and spatial navigation—skills that are usually damaged early in Alzheimer’s.
Chemical tests also revealed reduced inflammation and lower oxidative stress, both of which contribute to brain damage. Most importantly, the copper imbalance in the hippocampus, a key memory center, was corrected.
The treatment even reversed the pattern of beta‑amyloid plaque buildup, suggesting it may not only slow the disease but also partially undo some of the damage.
Safety is critical in early research like this, and the team carefully checked for harmful effects. The molecule was not toxic to brain cell cultures, and the treated animals showed normal vital signs throughout the experiments. Computer models also confirmed that the compound can reach the brain and target the right areas.
Alzheimer’s is extremely complex. It likely has many causes, which explains why no single treatment works for everyone. Current drugs, such as monoclonal antibodies, are expensive and can have serious side effects.
The molecule developed at UFABC is very simple and inexpensive to make, which is one reason the scientists are excited. Even if it helps only part of the population, it could still be a major step forward because it would offer a safer and more accessible option than many current treatments.
The research is now protected by a patent application, and the team is looking for pharmaceutical partners to begin human clinical trials. This is an essential step before any drug can be approved for medical use.
Clinical trials test safety, dosage, and effectiveness in people, and they can take several years. Still, the results so far give hope that this compound—or others like it—may eventually become part of a new generation of Alzheimer’s treatments focused on stopping the disease at its source.
When reviewing and analyzing the findings, it becomes clear that this study offers an exciting and practical approach to Alzheimer’s. By targeting copper imbalance, the molecule addresses a lesser-known but important factor in plaque formation. The ability to reverse biochemical markers and improve behavior in animals is especially promising.
However, it is important to remember that results in animals do not always translate directly to humans. More research is needed, but the simplicity, safety, and affordability of the compound make it a particularly strong candidate for further development.
If clinical trials confirm its benefits, it could help fill a major gap in global Alzheimer’s treatment, especially in low‑resource settings.
If you care about Alzheimer’s, please read studies about the likely cause of Alzheimer’s disease , and new non-drug treatment that could help prevent Alzheimer’s.
For more health information, please see recent studies about diet that may help prevent Alzheimer’s, and results showing some dementia cases could be prevented by changing these 12 things.
The study is published in ACS Chemical Neuroscience.
Copyright © 2025 Knowridge Science Report. All rights reserved.
